0000950170-22-016250.txt : 20220810 0000950170-22-016250.hdr.sgml : 20220810 20220810070530 ACCESSION NUMBER: 0000950170-22-016250 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 221150374 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 8-K 1 acet-20220810.htm 8-K 8-K
falseNONE000172058000017205802022-08-102022-08-100001720580dei:FormerAddressMember2022-08-102022-08-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2022

 

 

Adicet Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38359

81-3305277

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

200 Berkeley Street, 19th Floor

 

Boston, Massachusetts

 

02116

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 503-9095

 

 

200 Clarendon Street, Floor 6

Boston, Massachusetts 02116

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

ACET

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2022, Adicet Bio, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On August 9, 2022, the Company sold an aggregate of 2,611,723 shares of the Company’s common stock at a purchase price of $17.23 per share under its existing at-the-market agreement with JonesTrading Institutional Services, LLC. This resulted in aggregate gross proceeds to the Company of approximately $45.0 million, before deducting sales agent fees and expenses payable by the Company. The Company expects that current cash and cash equivalents of $304.3 million, as adjusted for sales agent fees from the at-the-market transaction on August 9, 2022, will be sufficient to fund its operating expenses into the first half of 2025.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

 

Description

99.1

 

Press release issued by Adicet Bio, Inc. on August 10, 2022, furnished herewith.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ADICET BIO, INC.

 

 

 

 

Date: August 10, 2022

 

By:

/s/ Nick Harvey

 

 

Name:

Nick Harvey

 

 

Title:

Chief Financial Officer

 

 EX-99.1 2 acet-ex99_1.htm EX-99.1 EX-99.1

 

Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates

 

ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL, as of May 31, 2022 data-cut date

 

ADI-001 received FDA Fast Track Designation

 

Strong balance sheet with $304.3 million in cash and cash equivalents, as adjusted for anticipated proceeds from at-the-market transaction

 

REDWOOD CITY, Calif. and BOSTON – August 10, 2022 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2022.

 

“During the second quarter of 2022, we made significant progress, achieving a number of clinical and regulatory milestones,” said Chen Schor, President and Chief Executive Officer at Adicet Bio. “We are particularly pleased with the positive clinical data from our lead product candidate ADI-001 presented at ASCO in June, and the Fast Track Designation by the FDA. We are excited to report that we are currently enrolling patients to dose level 4 (DL4) and are on track to potentially initiate at least one pivotal study during the first half of 2023. Our pipeline of preclinical programs is advancing, and we look forward to providing a more comprehensive update on several preclinical programs during the second half of 2022. With $304 million in cash and cash equivalents, as adjusted for the at-the-market transaction, we are capitalized into the first half of 2025 and expect to meet several meaningful milestones along the way, including during the second half of this year.”

 

Second Quarter 2022 and Recent Operational Highlights:

 

•
Received FDA Fast Track Designation for lead candidate ADI-001. In April, Adicet announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to ADI-001, an investigational therapy targeting CD20 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL).
•
Presented positive preclinical data at the ISCT Annual Meeting. In May, Adicet announced data from a preclinical evaluation of ADI-001 at the

 

ACTIVE/118242881.8

 

International Society for Cell and Gene Therapy (ISCT) Annual Meeting. The preclinical data showed that ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate activation pathways contributing to its anti-tumor activity. These cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches.
•
Presented positive interim data from the Phase 1 study of ADI-001 at the 2022 ASCO Annual Meeting. During the second quarter, Adicet presented positive data from the Phase 1 study of ADI-001 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the May 31, 2022 data-cut date, ADI-001 demonstrated 75% complete response (CR) and objective response rate (ORR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL.
•
Future development plans for ADI-001. In June, Adicet announced that given the safety profile to date, the Phase 1 study protocol was amended to include a new dose level – dose level 4 (DL4) (1E9 CAR+ cells) and a potential ADI-001 consolidation dosing at dose level 3 to finalize the recommended Phase 2 dose in the second half of 2022. The Company plans to provide at least one additional clinical update for the ADI-001 Phase 1 study in the second half of 2022. The Company also announced that it expects to discuss with the U.S. FDA and the European Medicines Agency (EMA) the design of two pivotal intent studies and a potential path to support a Biologics License Application (BLA) and Marketing Authorization Application (MAA) for ADI-001 and initiate at least one potentially pivotal study in the first half of 2023.
•
Moved Research & Development (R&D) operations to Redwood City, California; Establishing in-house manufacturing capacity. Adicet completed the move of its California operations to Redwood City, California for the purpose of establishing in-house manufacturing capabilities in the Redwood City facility to enable manufacturing for early clinical development of its potential clinical candidates. The manufacturing areas of the facility are expected to be operational in the fourth quarter of 2022.

Financial Results for Second Quarter 2022:

•
R&D Expenses: R&D expenses were $16.2 million for the three months ended June 30, 2022, compared to $10.6 million during the same period in 2021. The $5.6 million increase is primarily driven by a $2.5 million increase in payroll and personnel expenses resulting from an increase in headcount, a $1.4 million increase in contract manufacturing organization and other externally conducted R&D expense and a $0.7 million increase in contract research organization

 

ACTIVE/118242881.8

 

expense related to the Company’s Phase 1 trial. Payroll and personnel expenses for the three months ended June 30, 2022, includes $1.9 million of non-cash stock-based compensation expense compared to $0.8 million during the same period in 2021.
•
General and Administrative (G&A) Expenses: G&A expenses were $6.5 million for the three months ended June 30, 2022, compared to $5.0 million during the same period in 2021. The $1.5 million increase is primarily driven by an increase of $1.1 million of payroll and personnel expenses, which was partially offset by a $0.2 million decrease in professional service fees and a $0.2 million decrease in lab fees. Payroll and personnel expenses for the three months ended June 30, 2022, includes $2.4 million of non-cash stock-based compensation expense compared to $1.8 million during the same period in 2021.
•
Net Loss: Net loss attributable to common shareholders for the three months ended June 30, 2022 was $22.5 million, or a net loss of $0.56 per basic and diluted share, including non-cash stock-based compensation expense of $4.3 million, as compared to a net loss of $10.9 million during the same period in 2021, or a net loss of $0.34 per basic and diluted share, including non-cash stock-based compensation expense of $2.7 million.
•
Cash Position: Cash and cash equivalents were $260.6 million as of June 30, 2022, compared to $277.5 million as of December 31, 2021. On August 9, 2022, the Company sold an aggregate of 2,611,723 shares of the Company’s common stock at a purchase price of $17.23 per share under its existing at-the-market agreement. This resulted in aggregate gross proceeds to the Company of approximately $45.0 million, before deducting sales agent fees and expenses payable by the Company. The Company expects that current cash and cash equivalents of $304.3 million, adjusted for sales agent fees from the at-the-market transaction, will be sufficient to fund its operating expenses into the first half of 2025.

 

About Adicet Bio, Inc.

 

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable

 

ACTIVE/118242881.8

 

activity in patients. For more information, please visit our website at http://www.adicetbio.com.

 

Forward-Looking Statements

 

This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet including, but not limited to, preclinical and clinical development of Adicet’s product candidates, including future plans or expectations for ADI-001, potential safety, tolerability and therapeutic effects of ADI-001 and the planned release of interim clinical data from the Phase 1 trial in NHL patients; the advancement of Adicet’s preclinical pipeline programs; the launch of in-house manufacturing capabilities in Adicet’s Redwood City facility; and Adicet’s growth as a company and expectations regarding its uses of capital, expenses, future accumulated deficit and financial results, including the expected cash runway. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet’s business and financial results, including with respect to disruptions to our clinical trials, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy, including obtaining the requisite regulatory approvals on the expected timing, if at all; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

 

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

 

ACTIVE/118242881.8

 

abowdidge@adicetbio.com

 

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

 

ACTIVE/118242881.8

 

ADICET BIO, INC.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue—related party

 

$

—

 

 

$

4,814

 

 

$

24,990

 

 

$

833

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

16,178

 

 

 

10,616

 

 

 

29,661

 

 

 

22,359

 

General and administrative

 

 

6,529

 

 

 

5,025

 

 

 

13,330

 

 

 

10,655

 

Total operating expenses

 

 

22,707

 

 

 

15,641

 

 

 

42,991

 

 

 

33,014

 

Loss from operations

 

 

(22,707

)

 

 

(10,827

)

 

 

(18,001

)

 

 

(32,181

)

Interest income

 

 

325

 

 

 

9

 

 

 

357

 

 

 

50

 

Interest expense

 

 

(18

)

 

 

(51

)

 

 

(36

)

 

 

(101

)

Other expense, net

 

 

(138

)

 

 

(62

)

 

 

(240

)

 

 

(66

)

Loss before income tax provision (benefit)

 

 

(22,538

)

 

 

(10,931

)

 

 

(17,920

)

 

 

(32,298

)

Income tax provision (benefit)

 

 

—

 

 

 

(77

)

 

 

—

 

 

 

(125

)

Net loss

 

$

(22,538

)

 

$

(10,854

)

 

$

(17,920

)

 

$

(32,173

)

Net loss, basic and diluted

 

$

(0.56

)

 

$

(0.34

)

 

$

(0.45

)

 

$

(1.11

)

Weighted-average common shares used in computing net loss per share, basic and diluted

 

 

40,075,060

 

 

 

31,824,405

 

 

 

39,975,503

 

 

 

28,977,993

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on marketable debt securities, net of tax

 

 

—

 

 

 

(2

)

 

 

—

 

 

 

(24

)

Total other comprehensive loss

 

 

—

 

 

 

(2

)

 

 

—

 

 

 

(24

)

Comprehensive loss

 

$

(22,538

)

 

$

(10,856

)

 

$

(17,920

)

 

$

(32,197

)

 

 

ADICET BIO, INC.

Balance Sheet Data

(In thousands)

(unaudited)

 

 

 

June 30,
2022

 

 

December 31,
2021

 

Cash and cash equivalents

 

$

260,642

 

 

$

277,544

 

Working capital

 

 

247,690

 

 

 

266,121

 

Total assets

 

 

329,904

 

 

 

338,938

 

Contract liabilities – related party

 

 

—

 

 

 

4,805

 

Accumulated deficit

 

 

(186,244)

 

 

 

(168,324)

 

Total stockholders’ equity

 

 

293,267

 

 

 

303,129

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACTIVE/118242881.8

 

 EX-101.PRE 3 acet-20220810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 acet-20220810.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 acet-20220810_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 acet-20220810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Former Address [Member] Entity Addresses, Address Type [Axis] Address Type [Domain] XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Aug. 10, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2022
Entity Registrant Name Adicet Bio, Inc.
Entity Central Index Key 0001720580
Entity Emerging Growth Company true
Entity File Number 001-38359
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-3305277
Entity Address, Address Line One 200 Berkeley Street, 19th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02116
City Area Code (650)
Local Phone Number 503-9095
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ACET
Security Exchange Name NONE
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 200 Clarendon Street, Floor 6
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02116
XML 8 acet-20220810_htm.xml IDEA: XBRL DOCUMENT 0001720580 2022-08-10 2022-08-10 0001720580 dei:FormerAddressMember 2022-08-10 2022-08-10 false NONE 0001720580 8-K 2022-08-10 Adicet Bio, Inc. DE 001-38359 81-3305277 200 Berkeley Street, 19th Floor Boston MA 02116 (650) 503-9095 200 Clarendon Street, Floor 6 Boston MA 02116 false false false false Common Stock, par value $0.0001 per share ACET true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 2 23 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acet-20220810.htm acet-20220810.xsd acet-20220810_def.xml acet-20220810_lab.xml acet-20220810_pre.xml acet-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acet-20220810.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "acet-20220810_def.xml" ] }, "inline": { "local": [ "acet-20220810.htm" ] }, "labelLink": { "local": [ "acet-20220810_lab.xml" ] }, "presentationLink": { "local": [ "acet-20220810_pre.xml" ] }, "schema": { "local": [ "acet-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 1, "nsprefix": "acet", "nsuri": "http://www.adicetbio.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acet-20220810.htm", "contextRef": "C_8592d732-f8a3-4c01-80d5-982b12439e52", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acet-20220810.htm", "contextRef": "C_8592d732-f8a3-4c01-80d5-982b12439e52", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adicetbio.com/20220810/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r9": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0000950170-22-016250-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-016250-xbrl.zip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